CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DFLT3D835IPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
CBCL2F104IPredictiveSupportsResistanceFollicular LymphomaVenetoclaxBlombery et al., 2019
CBCR::ABL1Fusion AND ABL1 F317LPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DFLT3D835HPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DPIK3CAE545KPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAH1047RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAC420RPredictiveSupportsResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLV166F (c.496G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLG144* (c.430G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLF148* (c.443_455delinsA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseNordstrom-O'Brien et al., 2010
CVHLF76del (c.227_229del)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseRuiz-Llorente et al., 2004
CKANK1::NTRK2FusionDiagnosticSupportsPositivePilocytic AstrocytomaLópez et al., 2019
DPIK3CAK111NPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
DPIK3CAI391MPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumabBaselga et al., 2016
BERBB3OverexpressionPredictiveDoes Not SupportResistanceHer2-receptor Positive Breast CancerTrastuzumab EmtansineBaselga et al., 2016
DKRASWildtypePredictiveDoes Not SupportResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
CNRASQ61KPredictiveSupportsSensitivity/ResponseOvary Serous AdenocarcinomaTrametinibChamper et al., 2019
DKIAA1549::BRAFFusionPredictiveSupportsSensitivity/ResponseChildhood Pilocytic AstrocytomaSelumetinibSelt et al., 2017
CVHLNull (Large deletion)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseErlic et al., 2010
CNUP214::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2012
CRCSD1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CRANBP2::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CZMIZ1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CCENPC::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CNUP153::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CLSM14A::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
DNUP214::ABL1FusionPredictiveDoes Not SupportSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaPonatinib,Nilotinib,Dasatinib,ImatinibEyre et al., 2012
CZMIZ1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeBoer et al., 2017
CLSM14A::ABL1FusionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeTanasi et al., 2019
CSFPQ::ABL1FusionOncogenicSupportsOncogenicityB-lymphoblastic Leukemia/lymphomaHidalgo-Curtis et al., 2008
CRCSD1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeRoberts et al., 2012
CRCSD1::ABL1FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphomaDe Braekeleer et al., 2007
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaDasatinibKamran et al., 2015
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeTyrosine Kinase InhibitorYap et al., 2017
CRANBP2::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeDasatinibTanasi et al., 2019
CEGFRA763_Y764insFQEAPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
DPIK3CAC604RFunctionalSupportsGain of FunctionNg et al., 2018
DPIK3CAD350NFunctionalSupportsGain of FunctionNg et al., 2018
DSPOPE47KFunctionalSupportsLoss of FunctionZhang et al., 2015
DEGFRR222CFunctionalSupportsGain of FunctionNg et al., 2018
DSPOPE50KFunctionalSupportsLoss of FunctionZhang et al., 2015
DSPOPG75RFunctionalSupportsLoss of FunctionZhang et al., 2015
DSPOPS80RFunctionalSupportsLoss of FunctionZhang et al., 2015
DSPOPD140GFunctionalSupportsLoss of FunctionZhang et al., 2015
DKDRR1032QPredictiveSupportsSensitivity/ResponseColorectal CancerDovitinib,Lenvatinib,Axitinib,CabozantinibToledo et al., 2018
CSFPQ::ABL1FusionOncogenicSupportsOncogenicityB-lymphoblastic Leukemia/lymphomaTran et al., 2018
CEZH2Y646HPredictiveSupportsSensitivity/ResponseDiffuse Large B-cell LymphomaTazemetostatItaliano et al., 2018
DTP53C242FFunctionalSupportsLoss of FunctionJordan et al., 2010
Page 86 of 96
PreviousNext